Esophageal Cancer Radiation Management

Radiation therapy is indicated across the full spectrum of esophageal cancer , from early-stage disease to palliation. The choice of modality, definitive chemoradiotherapy (dCRT), neoadjuvant chemoradiotherapy (nCRT), adjuvant radiotherapy, or palliative RT, depends on tumor stage, histology, resectability, and patient fitness.

Early Stage (Stage I)

For stage I esophageal squamous cell carcinoma (ESCC), organ-sparing strategies are increasingly favored. Endoscopic resection (ER) followed by selective CRT based on pathology yields 3-year overall survival (OS) of 92.6% (90% CI, 88.5%-), comparable to esophagectomy ^[12]B2b. In this approach, patients with pT1b tumors or pT1a with lymphovascular invasion receive prophylactic CRT (41.4 Gy to locoregional nodes), while those with positive vertical margins receive definitive CRT (50.4 Gy with 9-Gy boost) ^[12]B2b. For cT1bN0M0 ESCC, definitive CRT alone is an option, but endoscopic findings of large size, type 0-I morphology, or B3 vessels predict higher risk of non-radical cure ^[16]C4. Brachytherapy as a boost after external beam RT ( EBRT ) for stage I disease shows 5-year locoregional control of 72% (63%-80%) and 5-year DFS of 63% (49%-76%) ^[7]B2a. After noncurative endoscopic submucosal dissection (ESD), adjuvant CRT is a viable alternative to esophagectomy, with no significant difference in OS or DFS and a low rate of grade ≥3 nonhematologic adverse events (6%) ^[17]B3b.

Locally Advanced (Stage II-III)

For resectable locally advanced esophageal cancer (≥T2 or ≥N1), neoadjuvant chemoradiotherapy followed by surgery is standard. The CROSS regimen ( carboplatin / paclitaxel with 41.4 Gy in 23 fractions) yields 3-year OS of 49.6% (95% CI, 40.4%-58.8%) in daily practice ^[18]B3b. Compared with neoadjuvant chemotherapy alone, nCRT increases R0 resection and pathologic complete response (pCR) rates, though without significant improvement in 3- or 5-year OS or PFS ^[1]A1a. Notably, approximately 16.8% of patients who start neoadjuvant therapy never undergo esophagectomy, most often due to disease progression (43.9%) or poor general condition (22.8%) ^[19]C4. For patients who achieve pCR after nCRT, active surveillance is under investigation; DCE-MRI with a qualitative grading system (G1-2) identifies pCR with sensitivity 73.5% and specificity 88.9% ^[13]B3b.

Unresectable Locally Advanced (Stage IVa)

Definitive chemoradiotherapy is the standard for unresectable locally advanced esophageal cancer. The standard radiation dose is 50 Gy in 25 fractions; a phase III trial showed no benefit for 60 Gy (HR 0.95 for LRPFS, P=0.761) and higher severe pneumonitis ^[11]A1b. Concurrent chemotherapy typically includes cisplatin plus 5-fluorouracil or docetaxel plus cisplatin ^{[4]A1b[11]A1b}. Event-free survival (EFS) is a strong surrogate for OS at the trial level (R²=0.80, 95% CI 0.38-0.96), with median EFS 17.5 months and median OS 25.1 months ^[3]A1a. For patients with concurrent cervical lymph node metastasis, neoadjuvant therapy followed by surgery is associated with longer survival (median OS 24.2 months) compared with dCRT alone (18.0 months; HR 0.56, 95% CI 0.34-0.91) ^[9]B2b.

Adjuvant (Post-Operative)

For stage IIB-IVA esophageal cancer after radical resection, adjuvant radiotherapy concurrent with weekly chemotherapy improves survival. In a retrospective series, 1-year and 3-year OS were 91.6% and 57.0%, respectively, with median OS 64.4 months ^[6]A1b. The number of concurrent chemotherapy cycles was an independent prognostic factor (P=0.010) ^[6]A1b. Adjuvant chemotherapy after nCRT and surgery may benefit patients with ypT+N+ disease, improving 5-year OS (24.8% vs. 29.9%, P=0.048) ^[15]B3b.

Palliative and Salvage

For locoregional recurrence after surgery, salvage radiotherapy (RT alone or CCRT) provides 2-year OS of 38.1% and PFS of 25.9% ^[14]C4. CCRT does not improve OS over RT alone (P=0.336) but shows a trend toward better PFS, at the cost of higher grade ≥3 toxicity (19.6% vs. 6.3%, P=0.023) ^[14]C4. In older adults (≥70 years) with ESCC, definitive RT alone is associated with higher treatment completion rates and lower toxicity compared with CCRT (adjusted RR 0.86 for completion; grade ≥3 toxicity 17.8% vs. 38.1%) ^[10]A1b.

Pearl: For unresectable locally advanced ESCC, 50 Gy remains the standard definitive dose; dose escalation to 60 Gy increases pneumonitis without improving survival ^[11]A1b.

Having determined the appropriate indication, the radiation oncologist must select the optimal EBRT technique, dose, and fractionation to maximize tumor control while respecting normal tissue tolerances. The choice of field design, modality, and dose prescription is guided by tumor stage, location, and patient factors, with the goal of balancing efficacy against acute and late toxicity.

Simulation and Target Volume Delineation

All patients undergo CT simulation in the supine position with arms raised, using a customized immobilization device ^[22]B3b. The gross tumor volume (GTV) includes the primary tumor and all clinically involved lymph nodes identified on imaging and endoscopy ^[21]B2a. For involved-field irradiation (IFI), the clinical target volume (CTV) is defined as the normal esophagus plus a 3 cm margin above and below the GTV, without elective nodal coverage ^[21]B2a. The planned target volume (PTV) is the CTV expanded by 1 cm in all directions for IFI, or by 5 mm when using IMRT with daily image guidance ^{[21]B2a[22]B3b}. For elective nodal irradiation (ENI), the CTV additionally includes regional lymph node stations at risk (e.g., supraclavicular, mediastinal, celiac) ^{[21]B2a[28]B3b}. Daily image-guided radiotherapy (IGRT) is recommended to reduce setup uncertainty and allow smaller PTV margins ^[25]B3b.

Irradiation Techniques: 3D-CRT , IMRT, and SIB-IMRT

Intensity-modulated radiotherapy (IMRT) is preferred over three-dimensional conformal radiotherapy (3D-CRT) because it improves target conformality and reduces off-target dose to the heart, lungs, and spinal cord ^[22]B3b. IMRT achieves superior dose distribution with fewer high-grade toxicities compared with 3D-CRT ^[22]B3b. Simultaneous integrated boost IMRT (SIB-IMRT) delivers a higher dose per fraction to the GTV while maintaining a standard dose (typically 60 Gy in 30 fractions) to the elective CTV ^[23]C4[27]D5. In a retrospective study of 302 patients, SIB-IMRT with a dose per fraction >2 Gy to the GTV significantly improved overall survival (median OS 30.0 months vs. 22.0 months; P=0.015) and disease-free survival without increasing grade ≥2 acute toxicities ^[27]D5. Another study comparing SIB-IMRT to standard-dose IMRT (60 Gy/30 fractions) after propensity-score matching reported a median OS of 22 months for SIB-IMRT versus 16 months for standard-dose IMRT, with 5-year OS rates of 27.3% and 8.7%, respectively ^[23]C4. SIB-IMRT appears safe and offers locoregional control advantages ^[23]C4[27]D5.

Charged-particle therapy ( proton beam therapy and carbon-ion radiotherapy) theoretically reduces dose to normal tissues by exploiting the Bragg peak ^[26]D5. Dosimetric studies show that proton therapy can lower heart and lung doses compared to IMRT ^[26]D5. However, no prospective trials have demonstrated a survival benefit over photon therapy, and its true clinical impact remains unclear ^[26]D5. Carbon-ion therapy additionally permits hypofractionated regimens, but clinical data are limited ^[26]D5.

Involved-Field vs. Elective Nodal Irradiation

The choice between IFI and ENI for definitive chemoradiotherapy remains debated. A meta-analysis of 23 studies (4120 patients, 97.6% with squamous cell carcinoma) found no significant differences in 1-, 2-, or 3-year overall survival (OS) between IFI and ENI, but IFI was associated with a significant improvement in 5-year OS (risk ratio [RR] 0.78; 95% CI 0.68-0.90; high certainty) after excluding one outlier study ^[21]B2a. In the IMRT subgroup, the 5-year OS benefit was more pronounced ^[21]B2a. IFI also reduced the incidence of grade ≥3 acute esophagitis (RR 0.51; 95% CI 0.38-0.69) and grade ≥2 acute esophagitis (RR 0.79; 95% CI 0.68-0.91) ^[21]B2a. No differences were observed in grade ≥3 pneumonitis or late toxicity ^[21]B2a. Conversely, a large retrospective study (924 patients) reported that ENI improved 5-year progression-free survival (18.4% vs. 12.7%) and OS (24.9% vs. 17.2%), particularly in young, male patients with cervical/upper thoracic tumors, early T stage, and tumor volume ≤50 cm³ ^[28]B3b. ENI also increased the risk of grade ≥2 bone marrow depression ^[28]B3b. These data suggest that IFI is appropriate for most patients, while ENI may be reserved for select subgroups at high risk of nodal failure.

Dose and Fractionation

Standard definitive radiotherapy dose is 60 Gy in 30 fractions (2 Gy per fraction, once daily, five days per week) ^{[22]B3b[23]C4[31]B3b}. In the meta-analysis, radiation doses ranged from 38 to 72 Gy with fraction sizes of 1.6 to 2.5 Gy, and the majority of patients received total doses ≥60 Gy ^[21]B2a. For patients with T1-2N0M0 disease, median dose of 60 Gy yielded 5-year OS of 53.2% and median OS of 70.1 months ^[31]B3b. Dose escalation beyond 60 Gy using SIB-IMRT may improve outcomes: a dose per fraction >2 Gy to the GTV was an independent prognostic factor for OS and DFS ^[27]D5. However, doses above 60 Gy with conventional fractionation have not been shown to improve survival in randomized trials. For patients receiving definitive radiotherapy alone (without chemotherapy), a median dose >60 Gy was used in 62.1% of patients, with a 2-year OS of 34.3% ^[24]B3b.

Organ-at-Risk Constraints

Normal tissue tolerance is critical to minimize toxicity. Table 1 summarizes commonly used OAR constraints derived from the available evidence. The spinal cord maximum dose should be kept below 45 Gy ^[22]B3b; in practice, mean maximum cord dose is approximately 39.7 Gy ^[31]B3b. Lung dose constraints include V20 ≤28% ^[22]B3b and mean lung dose around 10.8 Gy (though the reported range is wide) ^[31]B3b. Heart V30 should be limited to ≤14.2% on average ^[31]B3b; stomach V40 to ≤50% ^[22]B3b. IMRT and SIB-IMRT facilitate these constraints, while proton therapy may further reduce lung and heart exposure ^[26]D5.

Table 1: Organ-at-Risk Dose Constraints for Esophageal Cancer EBRT

Special Considerations

Sarcopenia, defined as a total psoas area <841.5 mm²/m² at L4, was associated with a 5.78-fold increased risk of acute grade ≥3 toxicity during neoadjuvant chemoradiotherapy, suggesting that pre-treatment body composition assessment may inform patient selection ^[25]B3b. In elderly patients (≥70 years), definitive IMRT with concurrent S-1 (oral fluoropyrimidine) yielded a median OS of 24 months and 3-year OS of 31.3%, with grade ≥2 esophagitis in 60% and hematologic toxicity in 45% ^[29]B3b. These data support the feasibility of modern EBRT across age groups.

After the completion of EBRT, brachytherapy can be considered for dose escalation in select patients with residual disease or for palliative management, as discussed in the next section.

Pearl: Organ-at-risk constraints (spinal cord <45 Gy, lung V20 ≤28%, heart V30 ≤15%, stomach V40 ≤50%) are achievable with IMRT and are critical to minimize toxicity.

For patients with stage I esophageal cancer or those requiring reirradiation, brachytherapy offers a dose-escalation strategy that exploits its steep dose gradient to spare adjacent organs at risk. Brachytherapy may be delivered as an exclusive treatment, as a boost after external beam radiotherapy ( EBRT ), or as reirradiation for local recurrence ^[7]B2a[32]C4.

Patient Selection and Risk Stratification

Candidate selection is guided by tumor stage, location, and prior treatment. Stage I (T1 N0) esophageal squamous cell carcinoma is the classic indication for brachytherapy with curative intent ^[7]B2a. Tumor length at brachytherapy, prescribed brachytherapy dose, and interfraction response are significantly associated with overall survival ^[32]C4. Patients unfit for surgery or EBRT alone, and those with local recurrence after previous radiation, may benefit from brachytherapy, but the evidence is Grade 1C (strong recommendation, low-quality evidence) ^[7]B2a.

Procedure and Dose Prescription

High-dose-rate (HDR) brachytherapy is the most common technique. Typical fractionation schemes include:

• Boost after EBRT: 3 fractions of 5 Gy each (total 15 Gy) prescribed to the applicator surface or at 5 mm depth.
• Exclusive brachytherapy or reirradiation: 6 fractions of 5 Gy each (total 30 Gy) prescribed at the applicator surface or at 5 mm ^[32]C4.

An alternative approach is the use of a self-expanding coated esophageal stent loaded with iodine-125 seeds. The radial cumulative dose from the stent is positively correlated with seed activity and negatively correlated with distance from the stent; the dose rate decreases rapidly with increasing distance, providing a high tumor dose while sparing deeper structures ^[35]D5.

Outcomes

In a systematic review of 525 patients, those receiving combined EBRT and brachytherapy had a 5-year mortality of 43% (95% CI 27-59%), 5-year disease-free survival of 63% (95% CI 49-76%), and 5-year locoregional control of 72% (95% CI 63-80%) ^[7]B2a. A second retrospective series reported median overall survival of 22 months in the boost setting, 25 months for exclusive brachytherapy, 15 months for reirradiation, and only 2 months for palliative brachytherapy; the 2-year survival rate for reirradiated patients was 19% ^[32]C4.

Table: Median overall survival by brachytherapy setting (data from Kissel et al. ^[32]C4). NR = not reported.

Toxicity

Complication rates are dose-dependent. Grade 1 esophagitis occurred in 82.1% of patients receiving combined EBRT and brachytherapy; ulcerations developed in 12.3% and fistulae in 3.3% ^[7]B2a. In another series, 40% of patients experienced grade 2 or higher toxicity (predominantly esophagitis), including three toxic deaths ^[32]C4.

Surveillance

After brachytherapy, patients should undergo regular endoscopic surveillance. In the series of patients treated with definitive CRT without brachytherapy, 38 of 42 local failures (90%) were successfully salvaged, most by endoscopic resection ^[33]B3b. The same principle applies to brachytherapy-treated patients, emphasizing the importance of close follow-up.

Controversies and Guideline Disagreement

The role of brachytherapy compared with dose-escalated EBRT or concurrent chemoradiotherapy (CRT) for superficial esophageal cancer remains debated. A large retrospective study of 123 patients with T1 esophageal cancer treated with CRT without brachytherapy reported a complete response rate of 94.4% and 5-year overall survival of 77.0%, suggesting that CRT alone may be sufficient for many patients with superficial disease ^[33]B3b. No randomized trials directly compare brachytherapy boost versus CRT alone for stage I disease.

Pearl: Brachytherapy’s steep dose gradient makes it uniquely suited for reirradiation of esophageal cancer, where 2-year survival of 19% can be achieved with acceptable toxicity, a meaningful option in a population with few alternatives ^[32]C4.

Brachytherapy plays a limited role in definitive management; for most patients with locally advanced esophageal cancer , concurrent chemoradiation (CRT) is the cornerstone of treatment. This approach is used both definitively for unresectable disease and as neoadjuvant therapy before surgery.

Standard Regimen and Dose

The standard definitive CRT regimen for esophageal squamous cell carcinoma (ESCC) delivers 50 Gy in 25 fractions with concurrent platinum-based chemotherapy. A phase III randomized trial comparing 60 Gy versus 50 Gy with concurrent weekly docetaxel (25 mg/m²) and cisplatin (25 mg/m²) found no difference in local/regional progression-free survival (HR 0.95, 95% CI 0.69-1.31), overall survival (HR 0.98, 95% CI 0.71-1.38), or progression-free survival (HR 0.93, 95% CI 0.68-1.26) ^[11]A1b. The 3-year OS rates were nearly identical (54.1% vs 54.0%). Importantly, the high-dose arm had a significantly higher rate of severe pneumonitis (P = 0.021) ^[11]A1b. 50 Gy should be the standard radiation dose for definitive CRT in ESCC.

Concurrent chemotherapy typically consists of cisplatin (80 mg/m²) and 5-fluorouracil (800 mg/m²/day continuous infusion on days 1-5) every 3 weeks, as used in landmark trials ^[36]A1b. Alternative regimens include weekly docetaxel plus cisplatin ^[11]A1b.

Role of Concurrent Chemotherapy

Compared with neoadjuvant chemotherapy alone, neoadjuvant CRT (nCRT) significantly increases the R0 resection rate and pathologic complete response (pCR) rate, though without a significant improvement in 3- or 5-year overall or progression-free survival ^[1]A1a. The addition of radiotherapy to chemotherapy thus improves local control but does not clearly extend survival in the neoadjuvant setting.

For definitive CRT, the combination of chemotherapy and radiation is synergistic. Event-free survival (EFS) serves as a valid surrogate for overall survival in definitive CRT trials, with a trial-level correlation R² of 0.80 (95% CI 0.38-0.96) across 11 randomized controlled trials ^[3]A1a. Median EFS was 17.5 months and median OS 25.1 months in these trials, suggesting EFS can estimate OS benefit approximately 8 months earlier ^[3]A1a.

Special Populations

Older adults (≥70 years): In a real-world cohort of 432 patients aged ≥70 with ESCC, CRT was associated with significantly lower treatment completion rates compared with radiotherapy alone (adjusted risk ratio 0.86, 95% CI 0.79-0.93; absolute risk difference -13.5%) ^[10]A1b. CRT also had higher rates of grade ≥3 toxicity (38.1% vs 17.8%; aRR 2.01), grade 4 toxicity (8.7% vs 2.3%; aRR 3.55), and 90-day unplanned readmission (21.6% vs 12.6%; aRR 1.72) ^[10]A1b. Effects were more pronounced in patients aged ≥75, those with Charlson Comorbidity Index ≥6, and frail patients (G8 ≤14). Careful patient selection is essential.

Cervical lymph node metastasis: In a Dutch nationwide cohort of 412 patients with thoracic esophageal cancer and concurrent cervical node metastasis, neoadjuvant therapy followed by surgery was associated with longer survival compared with definitive CRT (median OS 24 vs 18 months; HR 0.56, 95% CI 0.34-0.91) ^[9]B2b. Three-year OS rates were 38% vs 21%. However, interpretation is limited by baseline differences and potential residual confounding.

Weight loss during neoadjuvant therapy: Weight loss >5% during neoadjuvant chemotherapy is an independent risk factor for postoperative infectious complications (OR 2.69, 95% CI 1.12-6.46) ^[37]B2b. Weight maintenance should be prioritized.

Response Assessment

MRI: Diffusion-weighted MRI (DWI) has good predictive value for response to CRT. Pooled sensitivity and specificity for identifying response are 0.82 and 0.81, respectively, with an AUC of 0.88 ^[5]B2a. ADC values at week 2-3 of CRT are independent predictors of tumor response; a cutoff of 2.11 × 10⁻³ mm²/s at week 2 yields an AUC of 0.822 ^[39]C4. Dynamic contrast-enhanced MRI (DCE-MRI) using a qualitative grading system (G1-G5) can identify pathologic complete response after nCRT: G1 (compatible with CR) has 100% PPV and specificity, while combining G1 and G2 yields sensitivity 73.5%, specificity 88.9%, and accuracy 78.8% ^[13]B3b.

PET/CT: Change in SUV on interim ¹⁸F-FDG PET during nCRT has significant prognostic value. Pooled HRs for PFS and OS are 0.44 (95% CI 0.30-0.63) and 0.42 (95% CI 0.31-0.56), respectively ^[8]B2a. However, specificity for predicting pathologic response is modest (0.54).

Emerging Data

Immunotherapy combinations: In the KEYNOTE-590 Japanese subgroup (n=141), first-line pembrolizumab plus chemotherapy (cisplatin 80 mg/m² + 5-FU 800 mg/m²/day) significantly improved OS compared with chemotherapy alone (median 17.7 vs 11.7 months; HR 0.65, 95% CI 0.45-0.94) ^[36]A1b. The 60-month OS rate was 24.0% vs 8.5%. PFS was also improved (HR 0.57, 95% CI 0.39-0.83). Grade 3-4 treatment-related adverse events occurred in 74.3% vs 59.7% ^[36]A1b. This combination is now a standard first-line option for advanced esophageal cancer.

Induction chemotherapy followed by conversion surgery: The ongoing JCOG1510 (TRIANgLE) trial is evaluating induction docetaxel plus cisplatin and 5-fluorouracil (DCF) followed by conversion surgery or definitive CRT versus definitive CRT alone for locally advanced unresectable ESCC ^[4]A1b. Results are awaited.

Adjuvant chemotherapy after nCRT: In patients with ypT+N+ disease after nCRT and surgery, adjuvant chemotherapy improves 5-year OS (24.8% vs 29.9%, p=0.048) and reduces distant metastasis ^[15]B3b. Consideration should be given to adjuvant chemotherapy in this subgroup.

Pearl: The standard radiation dose for definitive CRT in ESCC is 50 Gy in 25 fractions; dose escalation to 60 Gy does not improve outcomes and increases pneumonitis ^[11]A1b. Concurrent cisplatin-based chemotherapy remains the backbone, with pembrolizumab now offering a survival benefit in the advanced setting ^[36]A1b.

After completing concurrent chemoradiation, the role of radiotherapy extends into the adjuvant and palliative settings, where it addresses locoregional control and symptom relief in distinct clinical scenarios.

Post-Operative Adjuvant Radiotherapy

For patients with resected thoracic esophageal squamous cell carcinoma (ESCC), adjuvant radiotherapy reduces locoregional recurrence (LRR). In a retrospective series of 195 patients, those receiving adjuvant RT (median 45 Gy) or chemoradiotherapy had significantly lower LRR compared with no adjuvant treatment (p < 0.05), while adjuvant chemotherapy alone did not reduce LRR ^[50]D5. Adjuvant concurrent chemoradiotherapy for stage IIB-IVA disease after radical resection achieved a 3-year overall survival (OS) of 57.0% and median OS of 64.4 months, with most acute toxicities being Grade 1-2 myelosuppression, esophagitis, and dermatitis ^[6]A1b. The number of concurrent chemotherapy cycles was an independent prognostic factor, but completion rates were low (41.6% received >5 weeks) ^[6]A1b. These data support adjuvant RT for LRR reduction, though patient selection remains critical.

Adjuvant Radiotherapy After Endoscopic Resection

For superficial esophageal cancer (cT1N0M0) with high-risk features (lymphovascular invasion or submucosal invasion), definitive-dose adjuvant radiotherapy (50-61.2 Gy) after endoscopic submucosal dissection (ESD) yields excellent outcomes. In a series of 44 patients, 5-year OS was 88.4% and disease-specific survival 97.7% ^[40]B3b. No lymph node recurrence occurred within the irradiated volume receiving ≥50 Gy ^[40]B3b. Age was the only independent prognostic factor. This approach offers an alternative to esophagectomy for selected patients.

Reirradiation

Reirradiation is challenging due to cumulative normal tissue toxicity. Brachytherapy offers a steep dose gradient that spares organs at risk. In a retrospective series, 36 patients received reirradiation with high-dose-rate brachytherapy (most commonly 6×5 Gy at applicator surface or 5 mm), achieving a median OS of 15 months and 2-year OS of 19% ^[32]C4. Grade 2+ toxicity occurred in 40%, including three toxic deaths ^[32]C4. Despite modest outcomes, reirradiation with brachytherapy may benefit selected patients with limited local recurrence.

Palliative Radiotherapy

Palliative radiotherapy (pRT) is used to relieve dysphagia, pain, and bleeding from the primary tumor or metastases. In a study of 132 patients with metastatic esophagogastric cancer, those who received pRT to the primary tumor after initial chemotherapy (with well-controlled metastatic disease) had a median OS of 23.3 months versus 14 months with chemotherapy alone (p < 0.001) ^[52]D5. pRT was an independent predictor of OS, and local progression was delayed (median time to local progression 17.3 vs 8.3 months) ^[52]D5. This suggests a role for consolidative pRT in selected patients.

For patients with cervical lymph node metastases, palliative RT alone (without chemotherapy) yielded a median OS of 7 months ^[9]B2b. In recurrent disease after curative surgery, median OS is poor (3.2 months overall), but selected patients receiving salvage-intent treatment achieved median OS of 13.6 months ^[41]B3b.

Stent placement is a mainstay for malignant dysphagia. Radiotherapy before stent insertion increases the risk of severe chest pain (7.6% vs 1.6%) ^[42]C4. Radiotherapy after stent insertion increases minor adverse events (56.5% vs 34.6%) but not life-threatening complications ^[42]C4. Low-radial-force stents (e.g., Niti-S) appear safe after prior RT, with major adverse event rates around 6% ^[53]D5. Radioactive stents (loaded with iodine-125 seeds) reduce stent restenosis compared with conventional stents (11.9% vs 27.0%; HR 0.387) without increasing major complications ^[49]B3b.

Photodynamic therapy (PDT) is an alternative palliative modality. It improves dysphagia in 90% of patients at 4 weeks and may prolong time to re-obstruction compared with stenting ^{[47]B2b[48]C4}. Median survival after PDT is approximately 7 months ^[47]B2b.

For symptomatic metastases (e.g., bone pain, bleeding, brain metastases ), palliative RT is commonly used, though specific outcome data in esophageal cancer are limited.

Pearl: In metastatic esophageal cancer with well-controlled systemic disease after chemotherapy, adding palliative radiotherapy to the primary tumor is associated with a median survival gain of over 9 months (23.3 vs 14 months) and should be considered in fit patients ^[52]D5.

Having discussed the applications of adjuvant and palliative RT, we now turn to the toxicity profile that accompanies these treatments. Radiation therapy for esophageal cancer carries a spectrum of acute and late adverse events that vary by treatment intent, technique, and patient factors.

Acute Toxicity

Acute esophagitis is the most common dose-limiting toxicity. In definitive chemoradiation, grade 3+ esophagitis occurs in approximately 10% of patients ^[23]C4. The addition of concurrent chemotherapy to RT significantly increases acute toxicity: in older adults (≥70 years), grade ≥3 toxicity rates were 38.1% with CCRT versus 17.8% with RT alone (aRR 2.01), and grade 4 toxicity was 8.7% versus 2.3% (aRR 3.55) ^[10]A1b. Radiation pneumonitis, particularly grade 5, was reported in the standard-dose IMRT group ^[23]C4. Acute hematologic toxicity is also common with concurrent chemotherapy.

When RT is combined with esophageal stenting, severe chest pain is more frequent if RT is given before stent placement (7.6% vs 1.6%) ^[42]C4. Conversely, RT after stent placement increases global adverse events (56.5% vs 34.6%), including ingrowth/overgrowth and gastroesophageal reflux ^[42]C4.

Late Toxicity

Late toxicities reflect cumulative radiation damage to mediastinal structures. Tracheobronchial necrosis (TBN) is a rare but life-threatening complication. In a nationwide Japanese study of 6370 esophagectomy patients, primary TBN (P-TBN, necrosis without anastomotic leak ) occurred in 0.75% overall, with rates of 2.0% after pharyngo-laryngo-cervical esophagectomy (PLCE), 5.4% after total pharyngo-laryngo-esophagectomy (TPLE), and 0.1% after subtotal esophagectomy ^[55]B3b. P-TBN severity was graded: Grade 1 (mucosal necrosis) in 62.5%, Grade 2 (transmural without fistula) in 33.3%, and Grade 3 (with fistula) in 4.2% ^[55]B3b. Healing rates were 96.7% for Grade 1, 93.8% for Grade 2, and 0% for Grade 3 ^[55]B3b. Preoperative chemoradiotherapy and salvage surgery were associated with higher P-TBN risk ^[55]B3b.

Cardiovascular disease and hypothyroidism are late consequences of mediastinal and cervical irradiation. For cervical esophageal cancer treated with definitive RT, the 5-year cumulative incidence of grade 2 hypothyroidism was 31.6%, and the 10-year incidence was 62.5%; for ≥grade 3 cardiovascular disease, the rates were 17.5% at 5 years and 21.3% at 10 years ^[56]C4.

Radiation-induced liver injury (RILI) can mimic metastases on FDG-PET-CT after neoadjuvant chemoradiotherapy, with an incidence of 3% in one series; focal FDG uptake in the caudate or left lobe in the high-dose area should raise suspicion for RILI rather than metastases ^[59]C4.

Esophagorespiratory fistula (ERF) is a severe complication that can arise from tumor progression or treatment. In patients with self-expanding metallic stents, SEMS-induced ERF occurred in 11% at a median of 129 days; risk factors included a stent flare of 28 mm (HR 2.05) and post-stent chemotherapy (HR 2.0) ^[57]B3b. Induction chemotherapy for patients with airway involvement carries a 6% TEF rate ^[61]C4. Biodegradable stents for refractory benign strictures carry a risk of fistula formation, particularly in patients with prior chemoradiotherapy; one death from esophago-left atrium fistula was reported ^[60]B2b.

Prevention and Management

Pearl: The risk of severe toxicity is substantially higher when chemoradiation is given to older adults (≥70 years) and those with comorbidities; careful patient selection is critical ^[10]A1b.

Having reviewed the toxicity profile, the clinician must weigh these risks against expected outcomes, which vary substantially by stage, treatment modality, and patient selection. For patients with unresectable locally advanced esophageal cancer treated with definitive chemoradiotherapy (dCRT), median overall survival (OS) across trials is 25.1 months, with median event-free survival (EFS) of 17.5 months ^[3]A1a. A trial-level correlation analysis of 11 randomized controlled trials (2812 patients) demonstrated a strong EFS-OS association (R² = 0.80; 95% CI 0.38-0.96), supporting EFS as a valid surrogate endpoint for OS in dCRT trials ^[3]A1a. In the KEYNOTE-590 Japanese subgroup (5-year follow-up), first-line pembrolizumab plus chemotherapy improved median OS to 17.7 months versus 11.7 months with chemotherapy alone (HR 0.65; 95% CI 0.45-0.94); 60-month OS rates were 24.0% and 8.5%, respectively ^[36]A1b. For patients with concurrent cervical lymph node metastasis, a Dutch nationwide cohort (n = 412) reported median OS of 24 months for neoadjuvant therapy followed by surgery, 18 months for dCRT, 15 months for chemotherapy alone, 7 months for palliative radiotherapy, and 3 months for best supportive care; 3-year OS rates were 38%, 21%, 10%, 2%, and 1%, respectively ^[9]B2b. Neoadjuvant therapy followed by surgery was associated with longer survival compared with dCRT (HR 0.56; 95% CI 0.34-0.91) after multivariable adjustment ^[9]B2b. In the second-line setting, nivolumab monotherapy yielded a median progression-free survival (PFS) of 5.1 months and median OS of 14 months, with a response rate of 23% and disease control rate of 45% ^[70]B2b. Occurrence of immune-related adverse events (irAEs) was independently associated with longer PFS (P = 0.003) in patients receiving immune checkpoint inhibitor combinations ^[78]C4. For early-stage disease treated with endoscopic submucosal dissection (ESD), long-term outcomes are excellent: 3-, 5-, and 8-year disease-free survival rates were 96.8%, 91.7%, and 86.4%, respectively, with corresponding OS rates of 98.4%, 96.6%, and 92.3% ^[79]B3b. Age (HR 1.018 per year) and prior esophageal cancer (HR 3.050) predicted poorer DFS ^[79]B3b. A meta-analysis of 11 trials (4869 patients) in resectable esophageal cancer found a strong correlation between recurrence-free/disease-free survival and OS (ρ = 0.89, P < 0.001), suggesting these early endpoints may serve as surrogates for OS in the resectable setting ^[76]B2a. Early metabolic response on interim ¹⁸F-FDG PET during neoadjuvant chemoradiotherapy also carries significant prognostic value: pooled HRs for PFS and OS were 0.44 (95% CI 0.30-0.63) and 0.42 (95% CI 0.31-0.56), respectively ^[8]B2a. Diffusion-weighted MRI further aids response prediction, with apparent diffusion coefficient (ADC) percent increase during treatment showing a mean difference of 21.06% between responders and non-responders (P < 0.01) ^[69]B2a.

Prognostic Factors

Pearl: In unresectable locally advanced esophageal cancer, EFS is a validated surrogate for OS at the trial level (R² = 0.80), enabling earlier efficacy assessment; clinically, performance status, nodal burden, and early metabolic response on PET or MRI remain the strongest individual prognosticators guiding treatment decisions.

Part of the Esophageal Cancer family. Cross-cutting management is split across dedicated child pages:

• Esophageal Cancer , diagnostic page (definition, epidemiology, staging, biomarkers, prognosis)
• Esophageal Cancer Surgical Management , operations by stage, fertility-sparing options, sentinel node mapping, adjuvant triggers (Sedlis / Peters)
• Esophageal Cancer Systemic Therapy , concurrent / adjuvant / metastatic chemotherapy, targeted therapy, immune checkpoint inhibitors
• Esophageal Cancer Palliative Care , early integration, symptom management, palliative procedures, end-of-life care
• Esophageal Cancer Surveillance and Follow-up , post-treatment surveillance schedule, late toxicity, survivorship, patient counselling
• Esophageal Cancer Recurrent and Metastatic Disease , local-regional salvage, distant metastatic systemic therapy, oligometastatic disease

Pearl: Use these links to hop between management modalities; the parent Esophageal Cancer page carries diagnosis + staging that informs every decision here.